Calamos Wealth Management LLC Purchases Shares of 1,735 Humana Inc. $HUM

Calamos Wealth Management LLC acquired a new position in Humana Inc. (NYSE:HUM) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 1,735 shares of the insurance provider’s stock, valued at approximately $301,000.

Other institutional investors have also recently made changes to their positions in the company. Montag A & Associates Inc. grew its position in Humana by 1,880.0% during the fourth quarter. Montag A & Associates Inc. now owns 99 shares of the insurance provider’s stock valued at $25,000 after buying an additional 94 shares during the period. CoreCap Advisors LLC increased its holdings in Humana by 54.4% in the fourth quarter. CoreCap Advisors LLC now owns 105 shares of the insurance provider’s stock valued at $27,000 after buying an additional 37 shares in the last quarter. Fideuram Asset Management Ireland dac acquired a new position in shares of Humana in the fourth quarter worth about $27,000. Reflection Asset Management acquired a new position in shares of Humana in the fourth quarter worth about $29,000. Finally, Rosenberg Matthew Hamilton boosted its stake in shares of Humana by 136.0% during the 4th quarter. Rosenberg Matthew Hamilton now owns 118 shares of the insurance provider’s stock worth $30,000 after acquiring an additional 68 shares in the last quarter. 92.38% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently commented on HUM shares. Morgan Stanley raised their target price on Humana from $217.00 to $249.00 and gave the company an “underweight” rating in a research report on Thursday, June 4th. Sanford C. Bernstein reiterated an “outperform” rating and set a $425.00 price target on shares of Humana in a research report on Wednesday, June 3rd. Piper Sandler reissued a “neutral” rating and issued a $254.00 price objective (up from $182.00) on shares of Humana in a report on Wednesday, May 13th. Deutsche Bank Aktiengesellschaft cut Humana from a “buy” rating to a “hold” rating in a research report on Wednesday, May 20th. Finally, TD Cowen upped their target price on Humana from $211.00 to $350.00 and gave the stock a “hold” rating in a research note on Tuesday. Two research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, fifteen have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $325.87.

Humana Stock Performance

HUM opened at $406.98 on Thursday. The firm has a market capitalization of $48.86 billion, a PE ratio of 43.53, a PEG ratio of 2.32 and a beta of 0.71. Humana Inc. has a twelve month low of $163.11 and a twelve month high of $415.00. The firm’s 50-day moving average price is $348.73 and its 200 day moving average price is $258.30. The company has a current ratio of 1.77, a quick ratio of 1.77 and a debt-to-equity ratio of 0.66.

Humana (NYSE:HUM) last released its quarterly earnings data on Wednesday, April 29th. The insurance provider reported $10.31 EPS for the quarter, beating analysts’ consensus estimates of $9.97 by $0.34. Humana had a net margin of 0.82% and a return on equity of 10.45%. The company had revenue of $39.65 billion during the quarter, compared to the consensus estimate of $39.37 billion. During the same quarter in the prior year, the firm earned $11.58 EPS. Humana’s quarterly revenue was up 23.5% on a year-over-year basis. Humana has set its FY 2026 guidance at 9.000- EPS. As a group, sell-side analysts expect that Humana Inc. will post 9.04 EPS for the current fiscal year.

Key Stories Impacting Humana

Here are the key news stories impacting Humana this week:

• Positive Sentiment: Zacks Research upgraded Humana (HUM) to strong-buy, signaling improved analyst confidence in the insurer’s outlook. Zacks upgrade report
• Positive Sentiment: Zacks Research raised earnings estimates across several periods, including FY2026 EPS to $9.04 and FY2027 EPS to $13.30, reinforcing the view that Humana’s earnings may improve materially over the next few years.
• Positive Sentiment: Truist Financial increased its price target on Humana to $415, close to the stock’s recent trading range, which can help validate the current rally. Truist price target raise
• Neutral Sentiment: Investors are also weighing commentary about whether Humana is already fully valued after its recent run, which may limit upside unless upcoming results confirm the improved earnings outlook. Yahoo Finance valuation article
• Neutral Sentiment: One article argues that Humana’s Q2 earnings need to catch up with the stock’s performance, meaning the market may be awaiting confirmation from the upcoming report before pushing the shares much higher. Seeking Alpha article
• Negative Sentiment: News that Humana’s agreement with Wexner Medical Center is set to end in October, and another report that its insurance network is terminating an agreement with Ohio State, could raise concerns about network disruption or member retention. Wexner Medical Center agreement article

Humana Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.